Literature DB >> 33376192

A mark of disease: how mRNA modifications shape genetic and acquired pathologies.

Eliana Destefanis1,2, Gülben Avşar2,3, Paula Groza2,4,5, Antonia Romitelli2,6,7, Serena Torrini2,6,7, Pınar Pir2,3, Silvestro G Conticello2,6,8, Francesca Aguilo2,4,5, Erik Dassi1,2.   

Abstract

RNA modifications have recently emerged as a widespread and complex facet of gene expression regulation. Counting more than 170 distinct chemical modifications with far-reaching implications for RNA fate, they are collectively referred to as the epitranscriptome. These modifications can occur in all RNA species, including messenger RNAs (mRNAs) and noncoding RNAs (ncRNAs). In mRNAs the deposition, removal, and recognition of chemical marks by writers, erasers and readers influence their structure, localization, stability, and translation. In turn, this modulates key molecular and cellular processes such as RNA metabolism, cell cycle, apoptosis, and others. Unsurprisingly, given their relevance for cellular and organismal functions, alterations of epitranscriptomic marks have been observed in a broad range of human diseases, including cancer, neurological and metabolic disorders. Here, we will review the major types of mRNA modifications and editing processes in conjunction with the enzymes involved in their metabolism and describe their impact on human diseases. We present the current knowledge in an updated catalog. We will also discuss the emerging evidence on the crosstalk of epitranscriptomic marks and what this interplay could imply for the dynamics of mRNA modifications. Understanding how this complex regulatory layer can affect the course of human pathologies will ultimately lead to its exploitation toward novel epitranscriptomic therapeutic strategies.
© 2021 Destefanis et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.

Entities:  

Keywords:  RNA modifications; cancer; epitranscriptomics; human disease; mRNA; posttranscriptional regulation of gene expression

Year:  2020        PMID: 33376192      PMCID: PMC7962492          DOI: 10.1261/rna.077271.120

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  315 in total

1.  APOBEC-mediated editing of viral RNA.

Authors:  Kate N Bishop; Rebecca K Holmes; Ann M Sheehy; Michael H Malim
Journal:  Science       Date:  2004-07-30       Impact factor: 47.728

Review 2.  Pseudouridine synthases.

Authors:  Tomoko Hamma; Adrian R Ferré-D'Amaré
Journal:  Chem Biol       Date:  2006-11

3.  Post-transcriptional modifications of mRNA. Purification and characterization of cap I and cap II RNA (nucleoside-2'-)-methyltransferases from HeLa cells.

Authors:  S R Langberg; B Moss
Journal:  J Biol Chem       Date:  1981-10-10       Impact factor: 5.157

4.  5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs.

Authors:  Xin Chen; Ang Li; Bao-Fa Sun; Ying Yang; Ya-Nan Han; Xun Yuan; Ri-Xin Chen; Wen-Su Wei; Yanchao Liu; Chun-Chun Gao; Yu-Sheng Chen; Mengmeng Zhang; Xiao-Dan Ma; Zhuo-Wei Liu; Jun-Hang Luo; Cong Lyu; Hai-Lin Wang; Jinbiao Ma; Yong-Liang Zhao; Fang-Jian Zhou; Ying Huang; Dan Xie; Yun-Gui Yang
Journal:  Nat Cell Biol       Date:  2019-07-29       Impact factor: 28.824

5.  RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients.

Authors:  W Vollmar; J Gloger; E Berger; G Kortenbruck; R Köhling; E-J Speckmann; U Musshoff
Journal:  Neurobiol Dis       Date:  2004-03       Impact factor: 5.996

6.  Pseudouridinylation of mRNA coding sequences alters translation.

Authors:  Daniel E Eyler; Monika K Franco; Zahra Batool; Monica Z Wu; Michelle L Dubuke; Malgorzata Dobosz-Bartoszek; Joshua D Jones; Yury S Polikanov; Bijoyita Roy; Kristin S Koutmou
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-31       Impact factor: 11.205

7.  Molecular cloning of an apolipoprotein B messenger RNA editing protein.

Authors:  B Teng; C F Burant; N O Davidson
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

8.  Development of metachronous rectal cancers in a young man with dyskeratosis congenita: a case report.

Authors:  Motoko Watanabe; Gou Yamamoto; Kenji Fujiyoshi; Yoshito Akagi; Miho Kakuta; Yoji Nishimura; Kiwamu Akagi
Journal:  J Med Case Rep       Date:  2019-04-27

Review 9.  Detection and Analysis of RNA Ribose 2'-O-Methylations: Challenges and Solutions.

Authors:  Yuri Motorin; Virginie Marchand
Journal:  Genes (Basel)       Date:  2018-12-18       Impact factor: 4.096

10.  m6A mRNA Methylation Regulates Human β-Cell Biology in Physiological States and in Type 2 Diabetes.

Authors:  Dario F De Jesus; Zijie Zhang; Sevim Kahraman; Natalie K Brown; Mengjie Chen; Jiang Hu; Manoj K Gupta; Chuan He; Rohit N Kulkarni
Journal:  Nat Metab       Date:  2019-07-29
View more
  4 in total

1.  APOBEC1 mediated C-to-U RNA editing: target sequence and trans-acting factor contribution to 177 RNA editing events in 119 murine transcripts in-vivo.

Authors:  Saeed Soleymanjahi; Valerie Blanc; Nicholas Davidson
Journal:  RNA       Date:  2021-06-03       Impact factor: 5.636

2.  MODOMICS: a database of RNA modification pathways. 2021 update.

Authors:  Pietro Boccaletto; Filip Stefaniak; Angana Ray; Andrea Cappannini; Sunandan Mukherjee; Elżbieta Purta; Małgorzata Kurkowska; Niloofar Shirvanizadeh; Eliana Destefanis; Paula Groza; Gülben Avşar; Antonia Romitelli; Pınar Pir; Erik Dassi; Silvestro G Conticello; Francesca Aguilo; Janusz M Bujnicki
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

3.  The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma.

Authors:  Wan He; Gengpeng Lin; Chaohu Pan; Wenwen Li; Jing Shen; Yangli Liu; Hui Li; Dongfang Wu; Xuejia Lin
Journal:  Front Genet       Date:  2022-01-28       Impact factor: 4.599

Review 4.  More than a duologue: In-depth insights into epitranscriptomics and ferroptosis.

Authors:  Justin Chak Ting Cheung; Guangzheng Deng; Nathalie Wong; Yujuan Dong; Simon Siu Man Ng
Journal:  Front Cell Dev Biol       Date:  2022-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.